Ads
related to: nivolumab- View Efficacy Data
Explore Efficacy & Safety Info
For OPDIVO® Treatment.
- Info On Financial Support
Visit Access And Support Site
And View Other Patient Resources.
- Mechanism Of Action
Review The Mechanism Of Action
For OPDIVO® Treatment Options.
- View Dosing Schedules
Find Dosing Information For This
Treatment Option Today.
- See Approved Indications
Explore The Indications For FDA
Approved Treatment Option OPDIVO®.
- See Safety Profiles
Read Important Safety Information
For FDA Approved OPDIVO®.
- View Efficacy Data
Search results
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Benzinga via Yahoo Finance· 11 hours agoThursday, Replimune Group Inc (NASDAQ:REPL) released topline results from the primary analysis of...
I-Mab and BMS assess givastomig for gastric and oesophageal cancer
Pharmaceutical Technology via Yahoo Finance· 19 hours agoI-Mab has announced a collaboration and supply agreement with Bristol Myers Squibb (BMS) to assess...
CG Oncology reports promising bladder cancer trial results By Investing.com
Investing.com· 10 hours agoCG Oncology, Inc. (NASDAQ: CGON), a biopharmaceutical company engaged in the development of oncology...
Neoadjuvant immunotherapy for early stage melanoma shows positive results
Medical Xpress· 3 days agoThe NADINA study, led by researchers from the Netherlands Cancer Institute, was named one of the...
Dual Immunotherapy Improves Response Rates in Gynecologic Clear Cell Cancers
MedPage Today· 3 days agoAmong 14 patients who received nivolumab alone, there were two partial responses and no complete...
BMS’ Opdivo-Yervoy treatment improves survival in hepatocellular carcinoma trial
Clinical Trials Arena via Yahoo Finance· 2 days agoBristol Myers Squibb (BMS) has announced findings from the Phase III CheckMate -9DW trial where...
Neoadjuvant Strategy Establishes Standard of Care for Resectable Stage III Melanoma
MedPage Today· 3 days agoCombination neoadjuvant immunotherapy for resectable melanoma reduced recurrence and other clinical...
I-Mab and Bristol Myers team up for cancer drug trial By Investing.com
Investing.com· 1 day agoThe trial will combine I-Mab's bispecific antibody givastomig with Bristol Myers Squibb’s immune...
S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat - Freight Technologies...
Benzinga· 9 hours agoReplimune Group, Inc. REPL shares shot up 24% to $6.91 as the company announced positive topline...
Rockville’s I-Mab, Bristol Myers Squibb to collaborate on new cancer study - Maryland Daily Record
The Daily Record· 1 day agoUnder the terms of the agreement, the study will be a multi-national Phase 1 study conducted by I-Mab. Bristol Myers Squibb will supply nivolumab. Nivolumab
Ad
related to: nivolumab